Medical Equipment/Supplies/Accessories · Founded 2004 · www.laxmidentallimited.com · BSE 544339 · NSE LAXMIDENTL · ISIN INE0WO601020
No Notes Added Yet
Business
Laxmi Dental Ltd. is an Indian company operating in the Medical Equipment/Supplies/Accessories sector, specifically focusing on the dental industry. While exact details of its operations are not publicly available from the provided information, it is highly probable that the company is involved in the manufacturing, distribution, or trading of a range of dental products. This could include dental instruments, consumables (e.g., composites, impression materials), laboratory equipment, and other accessories used by dentists, dental clinics, hospitals, and dental laboratories. The core business model would involve sourcing or producing these dental products and selling them to dental professionals, making money through sales revenue.
Revenue Mix
Specific key segments and their revenue contribution are not publicly available from the provided information. However, based on the industry, potential segments could include:
Dental Consumables: Materials like composites, bonding agents, impression materials, cements, and prophy pastes.
Dental Instruments: Hand instruments, rotary instruments, surgical instruments.
Dental Equipment: X-ray machines, dental chairs, sterilization units, curing lights.
Laboratory Products: Materials and equipment for dental labs producing crowns, bridges, dentures.
Without detailed financial reports, the actual revenue mix remains undisclosed.
Industry
The Indian dental equipment and supplies industry is a growing market, driven by increasing awareness of oral health, rising disposable incomes, and the expansion of dental care infrastructure. The industry is characterized by a mix of domestic manufacturers/distributors and international players who import and distribute advanced dental technology. Laxmi Dental Ltd. operates within this competitive landscape as a participant in the Indian dental supplies market. Its precise market share or specific positioning relative to larger domestic or international peers cannot be determined without further data. It likely caters to a segment of the Indian dental professional market, potentially leveraging a distribution network or specific product offerings.
MOAT
Based on the limited information, a definitive competitive advantage or "moat" for Laxmi Dental Ltd. cannot be established. Potential sources of competitive advantage, if they exist, could include:
Established Distribution Network: A robust network across India to reach a wide base of dentists and clinics.
Brand Reputation: A strong brand name and trust among Indian dental professionals for quality and service.
Cost Efficiency: Ability to manufacture or source products at a lower cost, allowing for competitive pricing.
Customer Relationships: Long-standing relationships with dental practitioners built on reliability and service.
Without specific details on its operations, it is difficult to ascertain the durability or strength of any such advantages.
Growth Drivers
Key factors that can drive growth for Laxmi Dental Ltd. over the next 3-5 years include:
Increasing Dental Healthcare Penetration: Rising awareness of oral health and demand for dental treatments in India.
Growth in Dental Professionals & Clinics: An expanding number of dentists, dental clinics, and hospitals.
Technological Advancements: Introduction of new and advanced dental products and technologies driving replacement demand and new procedures.
Rising Disposable Incomes: Enabling more Indians to afford elective and aesthetic dental procedures.
Expansion of Product Portfolio: Introducing new and innovative dental products to cater to evolving market needs.
Geographic Expansion: Deepening market penetration in existing regions and entering new markets within India.
Risks
Key business risks for Laxmi Dental Ltd. include:
Intense Competition: From both large multinational corporations and other domestic players, leading to pricing pressure and market share battles.
Regulatory Changes: Evolving regulations regarding medical device approval, quality standards, and import/export policies in India.
Supply Chain Vulnerability: Dependence on specific suppliers for raw materials or finished goods, especially for imported components or products.
Economic Downturns: A slowdown in the economy could impact discretionary dental spending, affecting sales.
Technological Obsolescence: Failure to keep pace with rapid advancements in dental technology could lead to loss of competitive edge.
Product Quality & Recalls: Issues with product quality or potential recalls could damage reputation and incur significant costs.
Management & Ownership
Specific details regarding the promoters, management quality, and ownership structure of Laxmi Dental Ltd. are not publicly available from the provided information. As an Indian company, it is likely promoted and managed by a founding family or a team of entrepreneurs. Without further data, it is not possible to comment on specific management strengths, board composition, or institutional ownership.
Outlook
Laxmi Dental Ltd. operates in the promising Indian dental supplies market, which is expected to benefit from demographic tailwinds, increased healthcare spending, and rising oral health awareness. This provides a supportive environment for potential growth. The company could leverage its position to expand its product offerings, strengthen its distribution network, and capitalize on the growing demand for dental care.
However, the industry is also highly competitive, with established international players and numerous domestic manufacturers. The company faces risks related to pricing pressure, regulatory changes, and the need for continuous innovation to keep pace with technological advancements. Its long-term success will likely depend on its ability to maintain product quality, expand its market reach efficiently, manage its supply chain effectively, and differentiate itself in a crowded market.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 48 | 55 | 60 | 57 | 62 | 61 | 66 | 72 | 66 | 74 |
| Other Income | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Total Income | 48 | 55 | 60 | 58 | 62 | 62 | 67 | 75 | 68 | 76 |
| Total Expenditure | 44 | 43 | 46 | 48 | 52 | 51 | 54 | 61 | 59 | 60 |
| Operating Profit | 4 | 12 | 14 | 9 | 10 | 11 | 14 | 13 | 9 | 16 |
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Exceptional Income / Expenses | 0 | -0 | 7 | 0 | 0 | 0 | 0 | 0 | -6 | 0 |
| Profit Before Tax | -0 | 7 | 16 | 5 | 5 | 6 | 10 | 9 | -1 | 11 |
| Provision for Tax | -1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | -2 | 1 |
| Profit After Tax | 1 | 6 | 14 | 4 | 4 | 4 | 7 | 8 | 1 | 11 |
| Adjustments | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | -1 |
| Profit After Adjustments | 2 | 8 | 17 | 6 | 5 | 4 | 8 | 9 | 2 | 10 |
| Adjusted Earnings Per Share | 0.2 | 2.7 | 6 | 2.1 | 0.9 | 0.8 | 1.5 | 1.6 | 0.4 | 1.8 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 137 | 162 | 194 | 239 | 278 |
| Other Income | 1 | 2 | 2 | 3 | 8 |
| Total Income | 138 | 164 | 195 | 242 | 286 |
| Total Expenditure | 131 | 152 | 169 | 196 | 234 |
| Operating Profit | 7 | 12 | 26 | 46 | 52 |
| Interest | 4 | 5 | 6 | 6 | 0 |
| Depreciation | 8 | 11 | 12 | 15 | 16 |
| Exceptional Income / Expenses | -9 | -0 | -0 | 7 | -6 |
| Profit Before Tax | -15 | -4 | 9 | 32 | 29 |
| Provision for Tax | 2 | 0 | -9 | 6 | 3 |
| Profit After Tax | -17 | -4 | 18 | 25 | 27 |
| Adjustments | -1 | 0 | 7 | 6 | 2 |
| Profit After Adjustments | -18 | -4 | 25 | 32 | 29 |
| Adjusted Earnings Per Share | -6.6 | -1.4 | 8.9 | 5.8 | 5.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 23% | 20% | 0% | 0% |
| Operating Profit CAGR | 77% | 87% | 0% | 0% |
| PAT CAGR | 39% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -49% | NA% | NA% | NA% |
| ROE Average | 21% | 20% | -30% | -30% |
| ROCE Average | 25% | 16% | 7% | 7% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 21 | 18 | 42 | 209 |
| Minority's Interest | 2 | 2 | 2 | 0 |
| Borrowings | 10 | 11 | 15 | 11 |
| Other Non-Current Liabilities | 10 | 8 | -4 | 2 |
| Total Current Liabilities | 59 | 58 | 66 | 57 |
| Total Liabilities | 103 | 97 | 123 | 278 |
| Fixed Assets | 39 | 39 | 45 | 51 |
| Other Non-Current Assets | 4 | 4 | 9 | 41 |
| Total Current Assets | 60 | 53 | 64 | 187 |
| Total Assets | 103 | 97 | 123 | 278 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | -11 | -14 | -10 | -16 |
| Cash Flow from Operating Activities | -2 | 15 | 8 | 44 |
| Cash Flow from Investing Activities | 3 | -9 | -11 | -29 |
| Cash Flow from Financing Activities | -4 | -2 | -3 | 111 |
| Net Cash Inflow / Outflow | -3 | 4 | -5 | 125 |
| Closing Cash & Cash Equivalent | -14 | -10 | -16 | 109 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | -6.63 | -1.43 | 8.94 | 5.78 |
| CEPS(Rs) | -3.13 | 2.36 | 10.78 | 7.35 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 3.41 | 2.23 | 11.13 | 37.54 |
| Core EBITDA Margin(%) | 4.49 | 6.11 | 12.6 | 17.84 |
| EBIT Margin(%) | -7.61 | 0.46 | 7.27 | 15.89 |
| Pre Tax Margin(%) | -10.75 | -2.64 | 4.4 | 13.31 |
| PAT Margin (%) | -12.48 | -2.75 | 9.27 | 10.61 |
| Cash Profit Margin (%) | -6.35 | 4.05 | 15.44 | 16.89 |
| ROA(%) | -16.65 | -4.46 | 16.3 | 12.64 |
| ROE(%) | -180.94 | -57.01 | 96.95 | 21.4 |
| ROCE(%) | -20.54 | 1.5 | 21.04 | 24.97 |
| Receivable days | 54.32 | 46.05 | 42.73 | 47 |
| Inventory Days | 78.69 | 60.66 | 46.15 | 33.1 |
| Payable days | 245.23 | 214.61 | 144.21 | 152.61 |
| PER(x) | 0 | 0 | 0 | 76.82 |
| Price/Book(x) | 0 | 0 | 0 | 11.83 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.29 | 0.26 | 0.27 | 9.8 |
| EV/Core EBITDA(x) | 5.44 | 3.46 | 2.03 | 50.94 |
| Net Sales Growth(%) | 0 | 18.11 | 19.75 | 23.53 |
| EBIT Growth(%) | 0 | 107.18 | 1780.75 | 170.09 |
| PAT Growth(%) | 0 | 73.96 | 503.26 | 41.44 |
| EPS Growth(%) | 0 | 78.37 | 723.64 | -35.33 |
| Debt/Equity(x) | 1.41 | 1.77 | 0.99 | 0.06 |
| Current Ratio(x) | 1.01 | 0.92 | 0.98 | 3.3 |
| Quick Ratio(x) | 0.51 | 0.5 | 0.6 | 2.97 |
| Interest Cover(x) | -2.42 | 0.15 | 2.54 | 6.16 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 41.7 | 41.7 | 41.7 | 41.7 | 41.77 |
| FII | 34.24 | 33.59 | 32.39 | 32.45 | 31.21 |
| DII | 12.86 | 14.31 | 11.85 | 10.83 | 10.52 |
| Public | 11.19 | 10.4 | 14.06 | 15.02 | 16.5 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 2.29 | 2.29 | 2.29 | 2.29 | 2.3 |
| FII | 1.88 | 1.85 | 1.78 | 1.78 | 1.72 |
| DII | 0.71 | 0.79 | 0.65 | 0.6 | 0.58 |
| Public | 0.62 | 0.57 | 0.77 | 0.83 | 0.91 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 5.5 | 5.5 | 5.5 | 5.5 | 5.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +23% | +20% | — | — |
| Operating Profit CAGR | +77% | +87% | — | — |
| PAT CAGR | +39% | — | — | — |
| Share Price CAGR | -49% | — | — | — |
| ROE Average | +21% | +20% | -30% | -30% |
| ROCE Average | +25% | +16% | +7% | +7% |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 41.7 | 41.7 | 41.7 | 41.7 | 41.77 |
| FII | 34.24 | 33.59 | 32.39 | 32.45 | 31.21 |
| DII | 12.86 | 14.31 | 11.85 | 10.83 | 10.52 |
| Public | 58.3 | 58.3 | 58.3 | 58.3 | 58.23 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 2.29 | 2.29 | 2.29 | 2.29 | 2.3 |
| FII | 1.88 | 1.85 | 1.78 | 1.78 | 1.72 |
| DII | 0.71 | 0.79 | 0.65 | 0.6 | 0.58 |
| Public | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 5.5 | 5.5 | 5.5 | 5.5 | 5.5 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.